Puranen J, Rönty H
Scand J Rheumatol Suppl. 1978(21):21-4.
The therapeutic effect and the tolerance of a new non-steriod anti-inflammatory compound, proquazone, were compared with those of ibuprofen in a double-blind, randomized study on patients with gonarthrosis. Totally 39 patients participated in the study: 19 patients in the proquazone group and 20 patients in the ibuprofen group. The two drugs were given in daily doses of 900 mg and 1200 mg respectively during 3 weeks. In both treatment groups a good result was achieved in more than 70% of the cases, but proquazone seemed to be more effective in reducing swelling and pain of knee. There were more side effects in the proquazone group than in the ibuprofen group, but they were generally mild and disappeared spontaneously. Only one patient in the proquazone group withdrew, because of epigastric discomfort.
在一项针对膝关节炎患者的双盲随机研究中,将一种新型非甾体抗炎化合物丙氧苯唑的治疗效果和耐受性与布洛芬进行了比较。共有39名患者参与了该研究:丙氧苯唑组19名患者,布洛芬组20名患者。在3周内,两种药物的日剂量分别为900毫克和1200毫克。在两个治疗组中,超过70%的病例取得了良好效果,但丙氧苯唑在减轻膝关节肿胀和疼痛方面似乎更有效。丙氧苯唑组的副作用比布洛芬组更多,但一般较轻且会自行消失。丙氧苯唑组只有一名患者因上腹部不适退出研究。